Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andriy Derkach

Showing results (71-80 of 135) with videos related to

Pageof 14
Sort By:
Nature Genetics|October 16, 2025
Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancersSetor Amuzu, Amy X Xie, Xuechun Bai, et al.
Breast Cancer Research : BCR|January 23, 2024
A genome-wide association study of contralateral breast cancer in the Women's Environmental Cancer and Radiation Epidemiology StudyXiaohui Sun, Anne S Reiner, Anh Phong Tran, et al.
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Journal of the National Cancer Institute|July 16, 2025
Polygenic risk of coronary artery disease for long-term survivors of breast cancerGordon P Watt, Anne S Reiner, Xiang Shu, et al.
Blood Advances|March 29, 2022
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemiaZachary D Epstein-Peterson, Andriy Derkach, Susan Geyer, et al.
Blood|April 14, 2022
BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformationBing Li, Wenbin An, Hua Wang, et al.
Cancer|August 7, 2025
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costsHannah Burton, Leora Boussi, David Nemirovsky, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
The American Journal of Clinical Nutrition|December 30, 2016
Identifying biomarkers of dietary patterns by using metabolomicsMary C Playdon, Steven C Moore, Andriy Derkach, et al.
Blood Advances|June 27, 2020
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failureBrian J Ball, Christopher A Famulare, Eytan M Stein, et al.
Pageof 14

Showing results (71-80 of 135) with videos related to

Sort By:
Pageof 14
Nature Genetics|October 16, 2025
Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancersSetor Amuzu, Amy X Xie, Xuechun Bai, et al.
Breast Cancer Research : BCR|January 23, 2024
A genome-wide association study of contralateral breast cancer in the Women's Environmental Cancer and Radiation Epidemiology StudyXiaohui Sun, Anne S Reiner, Anh Phong Tran, et al.
Nature Communications|August 28, 2021
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myelomaKylee H Maclachlan, Even H Rustad, Andriy Derkach, et al.
Journal of the National Cancer Institute|July 16, 2025
Polygenic risk of coronary artery disease for long-term survivors of breast cancerGordon P Watt, Anne S Reiner, Xiang Shu, et al.
Blood Advances|March 29, 2022
Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemiaZachary D Epstein-Peterson, Andriy Derkach, Susan Geyer, et al.
Blood|April 14, 2022
BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformationBing Li, Wenbin An, Hua Wang, et al.
Cancer|August 7, 2025
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costsHannah Burton, Leora Boussi, David Nemirovsky, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
The American Journal of Clinical Nutrition|December 30, 2016
Identifying biomarkers of dietary patterns by using metabolomicsMary C Playdon, Steven C Moore, Andriy Derkach, et al.
Blood Advances|June 27, 2020
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failureBrian J Ball, Christopher A Famulare, Eytan M Stein, et al.
Pageof 14